Αποτελέσματα Αναζήτησης
3 Οκτ 2011 · The phase III, randomized, placebo-controlled Sequential Tarceva in Unresectable NSCLC (SATURN; BO18192) study evaluated maintenance erlotinib in patients with nonprogressive disease following first-line platinum-doublet chemotherapy.
15 Οκτ 2010 · In the phase III SequentiAl Tarceva® in UnResectable NSCLC (SATURN; BO18192) study, maintenance therapy with erlotinib significantly increased progression-free and overall survival (PFS and OS) versus placebo in both the overall intention-to-treat (ITT) population and in patients with EGFR immunohistochemistry (IHC)-positive tumours . These ...
9 Ιουλ 2012 · Similar results have also been obtained with erlotinib in two phase III trials: the Chinese Optimal trial 28 and the European EURTAC trial (European Tarceva versus Chemotherapy). 29 The latter compared erlotinib therapy with platinum-based chemotherapy, representing the first head-to-head comparison of an EGFR-TKI versus chemotherapy in Western ...
7 Νοε 2008 · Results from two, multicenter, placebo-controlled, randomized, Phase III trials conducted in first-line patients with locally advanced or metastatic NSCLC showed no clinical benefit with the ...
20 Μαΐ 2010 · We designed the phase 3, placebo-controlled Sequential Tarceva in Unresectable NSCLC (SATURN; BO18192) study to assess use of erlotinib as maintenance therapy in patients with non-progressive disease following first-line platinum-doublet chemotherapy.
2 Αυγ 2009 · August 1, 2009 (San Francisco, California) — New results from the phase 3 SATURN trial show that erlotinib (Tarceva) maintenance therapy significantly improves overall survival in...
The Sequential Tarceva in Unresectable NSCLC (SATURN) study investigated the use of maintenance erlotinib following the completion of first-line chemotherapy.
